Neuronetics Inc

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neuronetics reports robust Q4 performance, eyes nurse practitioner opportunities

Neuronetics delivered a strong performance in Q4 2022, showcasing revenue growth, operational achievements, and strategic partnerships.
While facing challenges in managing losses and revenue fluctuations, the company is focused on key initiatives and opportunities for future growth.
By leveraging upcoming opportunities with nurse practitioners and addressing analyst inquiries, Neuronetics aims to navigate challenges and drive sustainable growth in 2023.

Neuronetics Inc reports revenue growth and strategic advancements in Q1 2023

Neuronetics Inc's Q1 2023 performance reflects revenue growth, operational advancements, and strategic initiatives aimed at driving market expansion and financial stability.
While facing challenges in gross margin decline and negative EBITDA, the company's focus on cost management, recovery from merger disruption, and revenue guidance raise position it for future success.
With opportunities in expanded patient access, market growth, and product enhancements, Neuronetics is poised to capitalize on its strengths and navigate challenges effectively in the coming quarters.

Neuronetics reports solid Q2 performance, eyes growth amidst challenges

Neuronetics demonstrated resilience and growth in Q2 2023, with revenue increases and strategic advancements in technology and policy.
While facing challenges from closures and relocations, the company remains focused on financial stability and operational efficiency.
Opportunities lie in new technology clearances, favorable policy changes, and the growing demand for TMS therapy education and services.
Overall, Neuronetics' performance, strengths, challenges, and opportunities position the company for continued growth and market impact.

Neuronetics Inc reports solid Q3 earnings, faces challenges in expenses

Neuronetics Inc (STIM) delivered a strong performance in Q3 2023, showcasing revenue growth and operational advancements.
While facing challenges in aligning revenue with operating expenses, the company maintains a solid financial position and pursues growth opportunities.
By focusing on enhancing patient care standards, expanding market reach, and optimizing financial performance, Neuronetics Inc aims to drive sustainable growth and value creation.

Neuronetics Inc posts record revenue in Q4 2023 earnings call

Neuronetics Inc delivered a strong Q4 performance with revenue growth and achieving positive cash flow for the first time. The company's focus on strategic initiatives, regulatory advancements, and revenue guidance for 2024 indicate a positive trajectory for growth and profitability.

Neuronetics Inc reports revenue growth and strategic partnerships in Q1

Neuronetics Inc's Q1 2024 performance reflects revenue growth, operational efficiency improvements, and a strong financial position.
Strengths include successful programs, strategic partnerships, and growth opportunities in new market segments.
Challenges in system sales and revenue collection highlight areas for improvement, while opportunities in market expansion and revenue growth are promising.
Overall, Neuronetics shows resilience, innovation, and a strategic focus on driving growth and improving patient outcomes.

Neuronetics Inc reports Q2 revenue decline, eyes growth opportunities

Neuronetics Inc faced revenue challenges due to a cybersecurity breach but showed resilience in key areas.
Strategic adjustments and positive program results indicate a focus on growth and market expansion.
Acquisition and new debt facility offer opportunities for future expansion and financial stability.

Neuronetics reports solid Q3 earnings, eyes profitability and growth

Neuronetics is focused on optimizing operations, profitability, and cash flow breakeven by Q3 2025.
Greenbrook acquisition approval and strong business position provide a foundation for future growth.
Challenges include managing treatment session weakness and debt levels while pursuing revenue growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.

MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced it has amended its term loan agreement with its current lenders, investment affiliates managed by SLR Investment Corp. (SLR), which was originally entered into on March 2, 2020 and subsequently amended on April 20, 2020 and December 2, 2020. This amendment includes modifications to the ability of the Company to extend the interest-only period, the reduction of certain revenue covenants, and the elimination of the final term loan tranche available to the Company.

Neuronetics Announces Amendment of Credit Facility with SLR Investment Corp.

Neuronetics (STIM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging 24.2% in 4 Weeks, Here's Why the Trend Might Reverse for Neuronetics (STIM)

The stock price of Neuronetics Inc (NASDAQ: STIM) increased by 14.89% in the most recent trading session. This is why it happened.

Neuronetics Stock (STIM): Why The Price Jumped

Technology is awarded for its advances in mental health Technology is awarded for its advances in mental health

NeuroStar Advanced Therapy for Mental Health Recognized as Top Neuromodulation Solution Provider in 2021

MALVERN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced certain preliminary unaudited fourth quarter and full year 2021 revenue results.

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results

Technology will save practitioners and patients time during motor threshold determination Technology will save practitioners and patients time during motor threshold determination

Neuronetics Announces 510(k) Clearance of MT Cap Technology for NeuroStar® Advanced Therapy for Mental Health

Healthcare Triangle

Petros Pharmaceuticals

3 biotech penny stocks to watch after Bellus Health (BLU) skyrockets. The post Biotech Penny Stocks To Buy After BLU Stock Explodes?

Biotech Penny Stocks To Buy After BLU Stock Explodes? 3 To Watch

Symposium to Highlight World's Largest Depression Outcomes Registry Symposium to Highlight World's Largest Depression Outcomes Registry

Neuronetics Announces Key Role for NeuroStar Advanced Therapy at 4th International Brain Stimulation Conference

MALVERN, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. A recording of the fireside chat is available on the investor relations page of the Company's website at ir.neuronetics.com. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest TMS company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from neurohealth conditions. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics' NeuroStar® Advanced Therapy system is today's leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder in adults with over four million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world's largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results. For safety information and indications for use, visit NeuroStar.com. Investor Contact: Mike Vallie or Mark KlausnerICR Westwicke443-213-0499 ir@neuronetics.com Media Contact: EvolveMKD646-517-4220 NeuroStar@evolvemkd.com

Neuronetics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q3 2021 Results - Earnings Call Transcript

MALVERN, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced its financial and operating results for the third quarter of 2021.

Neuronetics Reports Third Quarter 2021 Financial and Operating Results

Partnership Will Bring Non-drug NeuroStar® Advanced Therapy For Mental Health To Thousands of Patients Across the Southeast

Neuronetics and River Region Psychiatry Announce Exclusive Partnership

The Company honors one of its largest providers for helping patients overcome depression with NeuroStar Advanced Therapy for Mental Health The Company honors one of its largest providers for helping patients overcome depression with NeuroStar Advanced Therapy for Mental Health

Neuronetics Celebrates 235,000 Treatment Milestone for Success TMS

MALVERN, Pa., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release third quarter financial and operating results prior to market open on Tuesday, November 9, 2021. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call

Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for

MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, October 12th from Neuronetics, Inc. (NASDAQ: STIM), please note that the Safe Harbor Statement was inadvertently omitted. No changes were made to the content of the press release and the Safe Harbor Statement has been added, the corrected release follows:

CORRECTION - Neuronetics Announces Preliminary Revenue for Third Quarter 2021

System Innovations Improve Efficiencies for Healthcare Practices and Patients

Neuronetics Launches Upgrades of NeuroStar® Advanced Therapy for Mental Health

LOS ANGELES--(BUSINESS WIRE)---- $STIM #investors--The Law Offices of Frank R. Cruz Announces Investigation of Neuronetics, Inc. (STIM) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Neuronetics, Inc. (STIM) on Behalf of Investors

MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today provided preliminary revenue results for the third quarter of 2021.

Neuronetics Announces Preliminary Revenue for Third Quarter 2021

MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced a commercial agreement with Success TMS in which Success TMS will exclusively utilize Neuronetics' platform, NeuroStar Advanced Therapy for Mental Health, for the treatment of patients suffering from treatment-resistant major depressive disorder (MDD). In connection with the commercial agreement, the Company has made a strategic investment in Success TMS in the form of a $10 million term loan to further accelerate the growth of Success TMS' business.

Neuronetics Announces Commercial Agreement with Success TMS

Efforts feature mental health advocate and expert Dr. Melissa Shepard Efforts feature mental health advocate and expert Dr. Melissa Shepard

NeuroStar® Advanced Therapy Recognizes National Depression Education and Awareness Month With New Campaign Launch

Peer-Reviewed Paper is Largest Real-World Data Set of TMS Seizure Risk Across Device Manufacturers Peer-Reviewed Paper is Largest Real-World Data Set of TMS Seizure Risk Across Device Manufacturers

UPDATE - New Data Highlights NeuroStar® Advanced Therapy for Mental Health Safety Over H-Coil TMS

New Data Highlights NeuroStar® Advanced Therapy for Mental Health Safety Over H-Coil TMS

Industry-changing partnership will increase patient access to NeuroStar® Advanced Therapy for Mental Health Industry-changing partnership will increase patient access to NeuroStar® Advanced Therapy for Mental Health

Neuronetics and Zion Healing Announce First Franchise Model for TMS Clinics

New site enhances the user experience and offers expanded content for depression sufferers New site enhances the user experience and offers expanded content for depression sufferers

News for Neuronetics Inc Stock (STIM)